Filing Flows › Ligand Pharmaceuticals (LGND) › Stock forecast & fair value
Ligand Pharmaceuticals (LGND) stock forecast and price target
Ligand Pharmaceuticals (LGND) trades at $306.20. 12 analysts' median price target is $350.00 (+14%), from $247.00 to $406.00.
Ligand Pharmaceuticals' latest quarter
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for LGND stock?
The median of 12 analysts' 12-month targets is $350.00, +14% from $306.20; the range is $247.00 to $406.00. The average rating is strong buy.
Does Ligand Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is LGND stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.